Key result
Dabigatran and rivaroxaban are as safe and effective as standard of care in the treatment and prophylaxis of pediatric VTE, with comparable rates of adverse events and major bleeding.
Why the study?
Standardized anticoagulants were not comprehensively trialed in pediatric patients, prompting a need to evaluate adverse events of direct oral anticoagulants compared to standard of care to assist clinical decision-making.
Do DOACs have a similar safety profile regarding adverse events and bleeding compared to standard of care in pediatric patients with VTE?
Do DOACs have a similar safety profile regarding adverse events and bleeding compared to standard of care in pediatric patients with VTE?
Dabigatran and rivaroxaban are as safe and effective as standard of care for the treatment and prophylaxis of pediatric VTE, with comparable adverse event and bleeding profiles.
Venous thromboembolism (VTE) has an increasing rate of significance in pediatric patients. The currently standardized anticoagulants (unfractionated heparin, low molecular weight heparin and vitamin K antagonists) and their dose regimens were not comprehensively trialed in pediatric patients. Recently, several direct oral anticoagulants (DOACs) have been studied in clinical trials in the pediatric population and further trials are ongoing. Dabigatran etexilate and rivaroxaban results show that these DOACs are safe and efficient in the treatment and secondary prevention of pediatric VTE. This review will focus on adverse events (AEs) between specific DOACs reported in the clinical trials in children and compare them to standard of care. This will assist clinicians in decision making of selecting the right anticoagulation for their pediatric patients.
No takes yet. Share an insight, caveat, or question.
Bosch et al. (2022) conducted a review in Venous thromboembolism (VTE) (n=1,079). DOACs (Dabigatran and Rivaroxaban) vs. Standard of Care (LMWH, VKA, fondaparinux) or ASA was evaluated on Adverse events and bleeding events. Dabigatran and rivaroxaban are as safe and effective as standard of care in the treatment and prophylaxis of pediatric VTE, with comparable rates of adverse events and major bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: